1. FRI0370 Efficacy and safety of lesinurad (RDEA594), a novel URAT1 inhibitor, in combination with allopurinol in allopurinol-refractory gout patients: Results from a randomized, blinded, placebo-controlled, phase 2b extension study. (23rd January 2014) Authors: Perez-Ruiz, F.; Sundy, J.; Krishnan, E.; Hingorani, V.; Welp, J.; Rodgers, T.; Manhard, K.; Cravets, M.; Hagerty, D.; Quart, B. Journal: Annals of the rheumatic diseases Issue: Volume 71(2012)Supplement 3 Page Start: 439 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. FRI0373 Assessing patients that continue to flare despite apparent optimal urate lowering therapy. (23rd January 2014) Authors: Khanna, D.; Hagerty, D.; Mischler, R.; Morlock, R. Journal: Annals of the rheumatic diseases Issue: Volume 71(2012)Supplement 3 Page Start: 440 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. FRI0383 Majority of us patients would not meet the proposed acr gout treatment guideline goal of SUA <6 mg/dl. (23rd January 2014) Authors: Singh, J.; Hagerty, D.; Mischler, R.; Morlock, R. Journal: Annals of the rheumatic diseases Issue: Volume 71(2012)Supplement 3 Page Start: 444 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. FRI0397 Adherence to EULAR recommendations for the treatment of GOUT. (23rd January 2014) Authors: Khanna, P.; Hagerty, D.; Mischler, R.; Morlock, R. Journal: Annals of the rheumatic diseases Issue: Volume 71(2012)Supplement 3 Page Start: 448 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗